# EDGAR Filing Document

**Accession Number:** 0001693011
**File Stem:** 0001193125-25-132782
**Filing Date:** 2025-6
**Character Count:** 5669
**Document Hash:** 23afa0b43a80b9163d244469b4501d2c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-132782.hdr.sgml**: 20250602

**ACCESSION NUMBER**: 0001193125-25-132782

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250530

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20250602

**DATE AS OF CHANGE**: 20250602

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inozyme Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001693011
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475129768
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39397
- **FILM NUMBER:** 251013149

**BUSINESS ADDRESS:**
- **STREET 1:** 321 SUMMER STREET
- **STREET 2:** SUITE 400
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 857-330-4340

**MAIL ADDRESS:**
- **STREET 1:** 321 SUMMER STREET
- **STREET 2:** SUITE 400
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Inozyme Pharma, LLC
- **DATE OF NAME CHANGE:** 20161222

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): May 30, 2025

## INOZYME PHARMA, INC.

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39397** | **38-4024528** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **321 Summer Street, Suite 400** |  |
| **Boston, Massachusetts** | **02210** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (857) 330-4340

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>symbol(s)** | **Name of each exchange<br>on which registered** |
| Common stock, par value $0.0001 per share | INZY | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed, on May 16, 2025, Inozyme Pharma, Inc., a Delaware corporation (the "**Company**"), BioMarin Pharmaceutical, Inc., a Delaware corporation ("**Parent**"), and Incline Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent, entered into an Agreement and Plan of Merger (the "**Merger Agreement**").

On May 30, 2025, in connection with the signing of the Merger Agreement, the compensation committee of the Board of Directors of the Company approved the grant of transaction bonuses to certain key employees including the following executive officers: Mr. Sanjay Subramanian, the Company's Chief Financial Officer and Head of Business Development, and Dr. Matthew Winton, the Company's Senior Vice President and Chief Operating Officer. The Company entered into transaction bonus agreements with each of Mr. Subramanian and Dr. Winton (collectively, the "**Transaction Bonus Agreements**") pursuant to which Mr. Subramanian and Dr. Winton will each be entitled to receive a cash bonus in the amount of $350,000 and $320,000, respectively, following the closing of the transactions contemplated by the Merger Agreement (the "**Closing Date**"). Payment of the transaction bonuses will be subject to the applicable executive's continued employment with the Company through the Closing Date, and will be paid within thirty (30) days following the Closing Date.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **INOZYME PHARMA, INC.** | **INOZYME PHARMA, INC.** |
| Date: June 2, 2025 | By: | /s/ Douglas Treco |
|  | Name: | Douglas Treco |
|  | Title: | Chief Executive Officer |

---